Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | CTH | P32929 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1134009 | 1.00 | NOS3 (0.33) | NOS3NOS1NOS2CTHLMNA | |
| SCHEMBL17841798 | 1.00 | NOS3 (0.33) | NOS3NOS1NOS2CTHLMNA | |
| SCHEMBL4734335 | 0.85 | MEN1 (0.41) | NOS3NOS1NOS2 | |
| SCHEMBL18059962 | 0.85 | MEN1 (0.41) | NOS3NOS1NOS2 | |
| SCHEMBL23754647 | 0.84 | NOS3 (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL22588782 | 0.81 | HSD17B10 (0.43) | NOS3NOS1NOS2 | |
| SCHEMBL25289772 | 0.81 | TSHR (0.35) | NOS3NOS1NOS2 | |
| SCHEMBL15020184 | 0.81 | — | — | |
| SCHEMBL29283298 | 0.80 | GLP1R (0.32) | — | |
| SCHEMBL5505638 | 0.80 | CTH (0.33) | NOS3NOS1NOS2CTHLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570610-B2 | Macromolecule-supported aminobenzazepine compounds | BOLT BIOTHERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250263392-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-20220315537-A1 | MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| EP-3983080-A1 | MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS | Bolt Biotherapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020252254-A1 | MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20200390899-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263392-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | IDO2, IDO1, BCR | NOS3 2382/4885NOS1 3869/4885NOS2 2549/4885 |
| US-20220315537-A1 | MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS | CCNB1, CCNB2, MUS81 | NOS3 2635/4885NOS1 3697/4885NOS2 2895/4885 |
| US-20200390899-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | IDO2, IDO1, BCR | NOS3 2382/4885NOS1 3869/4885NOS2 2549/4885 |
| US-12570610-B2 | Macromolecule-supported aminobenzazepine compounds | BCL6, CLTB, MET | NOS3 3949/4885NOS1 4296/4885NOS2 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.